Lanreotide is not a chemotherapy drug. It belongs to a different drug class called somatostatin analogs, which work by mimicking a natural hormone in your body rather than killing cells the way traditional chemotherapy does. Even though lanreotide is used to treat certain types of cancer, its mechanism, side effect profile, and impact on daily life are fundamentally different from cytotoxic chemotherapy.
How Lanreotide Actually Works
Your body naturally produces a hormone called somatostatin, which acts as a brake on various growth signals. Lanreotide is a synthetic version of that hormone. Once injected, it binds to the same receptors that natural somatostatin uses and slows down the release of growth-promoting hormones and growth factors. This is a targeted, regulatory approach. It tells overactive cells to calm down rather than poisoning them outright.
Traditional chemotherapy drugs are cytotoxic, meaning they kill rapidly dividing cells throughout the body. That’s why chemo causes hair loss, severe nausea, and immune suppression: it can’t distinguish between cancer cells and healthy cells that also divide quickly. Lanreotide doesn’t work this way. Its anti-tumor effects come from blocking the signals that help tumors grow, cutting off their blood supply formation, and in some cases triggering a natural cell death process, all while leaving healthy tissue largely alone. Research published in Annals of Oncology describes somatostatin analogs as an “innovative and less cytotoxic” alternative with “good tolerability and safety profiles.”
What Lanreotide Is Approved to Treat
The FDA has approved lanreotide (sold as Somatuline Depot) for two conditions:
- Acromegaly: a hormonal disorder where the body produces too much growth hormone, usually because of a pituitary tumor. Lanreotide is used when surgery or radiation hasn’t fully controlled the condition.
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): slow-growing tumors that arise in the digestive system or pancreas. Lanreotide is approved for cases that are locally advanced or have spread and can’t be surgically removed.
The acromegaly use isn’t cancer-related at all. For GEP-NETs, the goal is to slow tumor progression rather than shrink tumors aggressively, which is another key distinction from chemotherapy.
How Effective It Is for Neuroendocrine Tumors
The landmark CLARINET trial, published in The New England Journal of Medicine, tested lanreotide against a placebo in patients with advanced neuroendocrine tumors. The results were significant: lanreotide cut the risk of tumor progression or death by 53%. At the two-year mark, 65% of patients on lanreotide were still progression-free, compared to 33% on placebo. The median progression-free survival in the lanreotide group was so long it hadn’t even been reached by the time the study ended, while the placebo group’s median was 18 months.
These results show that lanreotide meaningfully slows disease progression, though it typically stabilizes tumors rather than causing them to shrink dramatically. For the type of slow-growing tumors it treats, stabilization can translate into years of additional time.
What Treatment Looks Like
Lanreotide is given as a deep injection under the skin in the upper outer area of the buttock, alternating sides each time. The standard schedule is once every four weeks. For neuroendocrine tumors, the dose is 120 mg every four weeks. For acromegaly, patients typically start at 90 mg every four weeks, with the dose adjusted up to 120 mg or down to 60 mg based on how well their hormone levels respond. Some patients with well-controlled acromegaly can eventually stretch their injections to every six or eight weeks.
This is a very different experience from chemotherapy, which often involves hours-long infusions, multi-drug regimens, and cycles of treatment followed by recovery periods. Lanreotide injections take minutes, and most people resume normal activity immediately afterward.
Side Effects Compared to Chemotherapy
The side effect profile of lanreotide reinforces that it is not chemotherapy. You won’t experience hair loss, severe immune suppression, or the kind of debilitating fatigue that defines many chemo regimens. The most common issues are gastrointestinal: diarrhea (37% of patients in acromegaly studies), abdominal pain (19%), and nausea (11%). Most of these are mild to moderate, and only about 1% of patients in clinical trials stopped treatment because of GI symptoms.
Gallstones are a notable concern. In clinical studies, 20% of acromegaly patients developed gallstones or gallbladder sludge during treatment, with 12% developing new gallstones they didn’t have before. This happens because somatostatin analogs reduce gallbladder contractions, allowing bile to stagnate. Your doctor will typically monitor your gallbladder with periodic ultrasounds.
In the neuroendocrine tumor trial, other reported side effects included musculoskeletal pain (19%), headache (16%), elevated blood sugar (14%), high blood pressure (14%), and injection site reactions (15%). While these deserve attention, they’re manageable for most people and a far cry from the systemic toxicity of chemotherapy.
Why the Confusion Happens
The confusion is understandable. Lanreotide treats cancer, it’s prescribed by oncologists, and it may be part of a broader cancer treatment plan that also includes chemotherapy or other therapies. In some cases, insurance companies even categorize it under oncology benefits. But pharmacologically, it sits in an entirely different category. It’s a hormone therapy, not a cytotoxic agent. If your oncologist has prescribed lanreotide, the treatment experience will be considerably less disruptive to your daily life than what most people associate with “chemo.”